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Background: Bone metastases are an important clinical issue in women with breast cancer. Particularly, unstable
spinal bone metastases (SBM) are a major cause of severe morbidity and reduced quality of life (QoL) due to frequent
immobilization. Radiotherapy (RT) is the major treatment modality and is capable of promoting re-ossification and
improving stability. Since local therapy response is excellent, survival of these patients with unstable SBM is of high
clinical importance. We therefore conducted this analysis to assess survival and to determine prognostic factors for
bone survival (BS) in women with breast cancer and unstable SBM.
Methods: A total population of 92 women with unstable SBM from breast cancer who were treated with RT at our
department between January 2000 and January 2012 was retrospectively investigated. We calculated overall survival
(OS) and BS (time between first diagnosis of bone metastases until death) with the Kaplan-Meier method and assessed
prognostic factors for BS with a Cox regression model.
Results: Mean age at first diagnosis of breast cancer was 60.8 years ± SD 12.4 years. OS after 1, 2 and 5 years was
84.8, 66.3 and 50 %, respectively. BS after 1, 2 and 5 years was 62.0, 33.7 and 12 %, respectively. An age > 50 years
(p < .001; HR 1.036 [CI 1.015–1.057]), the presence of a single bone metastasis (p = .002; HR 0.469 [CI 0.292–0.753])
and triple negative phenotype (p < .001; HR 1.068 [CI 0.933–1.125]) were identified as independent prognostic
factors for BS.
Conclusions: Our analysis demonstrated a short survival of women with breast cancer and unstable SBM. Age,
presence of a solitary SBM and triple-negative phenotype correlated with survival. Our results may have an impact
on therapeutic decisions in the future and offer a rationale for future prospective investigations.
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Metastases in women with breast cancer most frequently
occur in the skeleton [1]. Up to 2.6 % of all breast cancer
patients already present with bone metastases at initial
diagnosis and up to 15 % will develop bone metastases
within 15 years [2, 3]. Particularly, metastases of the
spinal column are a major cause of severe morbidity and
reduced quality of life due to severe pain, pathological frac-
tures, spinal cord compression and hypercalcemia [4, 5].
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pedic corset for the prevention of vertebral fractures
and possible spinal cord compression. Treatment of
SBM is multimodal including radiotherapy (RT), sur-
gery and systemic treatments such as bisphosphonates
[6]. Most commonly patients are treated with RT [7, 8]
and a frequent treatment indication is instability [9]. In
previous studies we were able to show that RT is cap-
able of promoting re-ossification leading to increased
stability of SBM. In those studies the analyzed patients
showed only minor cancer-related morbidity during
follow-up and reached comparably high survival rates.
Additionally, we showed that the use of a validated
scoring system to assess the stability of spinal bonearticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Patients’ characteristics
Number Percent
Age (mean, SD) 60.8 (±12.4)
KPS ≤70 35 38.0
>70 57 62.0
Localization thoracic 67 72.8
lumbar 25 27.2
Chemotherapy before RT yes 53 57.6
no 39 42.4
Radiological response at 3 months
after RT
yes 29 31.5
no 63 68.5
Radiological response at 6 months
after RT
yes 42 45.7
no 50 54.3
Bisphosphonates yes 85 92.4
no 7 7.6
Distant metastases brain 6 6.5
lung 13 14.1
liver 19 20.6
skin 2 2.2
Number of metastases solitary 33 35.9
multiple 59 64.1
Orthopedic corset yes 33 35.9
no 59 64.1
Pathological fracture before RT yes 6 6.5
no 86 93.5
Molecular phenotype luminal A 55 59.8
luminal B 8 8.7
HER2 9 9.8
triple
negative
20 21.7
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of instability [10–12]. Since local therapy response is
excellent, survival represents a major clinical interest in
these patients with unstable SBM. Therefore, we con-
ducted this analysis to assess survival and to determine
prognostic factors for bone survival (BS) in women with
unstable SBM from breast cancer.
Methods
A total population of 92 patients with histologically di-
agnosed breast cancer and unstable SBM were treated
with RT at the University Hospital Heidelberg between
January 2000 and January 2012. All patients were in-
cluded in this retrospective analysis. Inclusion criteria
were an osteolytic phenotype, unstable vertebral body,
location in the thoracic or lumbar spine and a mini-
mum duration of follow-up treatment of six months. A
total of 344 bone lesions in the thoracic and lumbar
spine were identified in these patients. Bone metastases
diagnoses were verified by computed tomography (CT).
Many patients exhibited more than one treated lesion;
only one lesion per vertebral body was included in the
analysis. Bone metastases distal to the irradiated site
were not included. The patients’ data were taken from
the Heidelberg NCT Cancer Registry and are summa-
rized in Table 1. Performance status was expressed
using the Karnofsky Performance Status score (KPS)
[13]. The specifications for an unstable vertebral body
were tumor occupancy of more than 60 % of the verte-
bral body and pedicle destruction [14]. This study was
approved by the Heidelberg Ethics Committee on 22
October 2012 (# S-513/2012).
BS was defined as the time from initial diagnosis of
SBM until death from any cause. The time of site ir-
radiation was not equal to the time of initial diagnosis
of bone metastases. Overall survival (OS) was defined
as time from initial diagnosis of breast cancer until
death from any cause. We estimated patients’ survival
using the Kaplan-Meier method. Patients were cen-
sored on the basis of whether or not they were alive.
Results were reported as the p-values of the log-rank
tests. Multivariate analysis was performed to detect fac-
tors independently associated with BS using a Cox pro-
portional hazards model. This regression analysis was
performed by including the factors age (>50 years),
Karnofsky Performance Status score (≤70 %), chemo-
therapy (ChT) prior to RT (no ChT), number of metas-
tases (solitary metastasis), local response (response after 3
or 6 months), concomitant bisphosphonates (no bispho-
sphonates), orthopedic corset (no corset) and pathological
fractures (no fracture). The results were reported as
p-values, hazard ratios and 95 % confidence intervals (CI).
For all analyses, a p-value of 0.05 or less was considered
statistically significant. All statistical analyses were doneusing the SAS software version 9.3 (SAS Institute, Cary,
NC, USA).
RT was carried out at the clinic of our department.
After CT-assisted three-dimensional-simulation, RT was
performed with 2-3 dorsal photon beams in the 6-MV
energy range. The planning target volume (PTV) cov-
ered the specific vertebral body affected, as well as those
immediately above and below it. The median individual
dose in all patients was 3 Gy; the median total dose
30 Gy. The respective fraction and total doses were
planned separately for each individual patient, depending
on tumor histology, the patient’s general state of health,
the current staging and respective prognosis.
Results
Mean age at first diagnosis of breast cancer was 60.8 years ±
SD 12.4 years. OS rates after 1, 2 and 5 years were 84.8,
Fig. 2 Bone survival
Table 2 Cox regression model of prognostic factors for bone
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1 year, 33.7 % after 2 years and 12.0 % after 5 years re-
spectively (Fig. 2). Among the investigated possible prog-
nostic factors only an age > 50 years (p < .001; HR 1.036
[CI 1.015–1.057]), the presence of a single bone metastasis
(p = .002; HR 0.469 [CI 0.292–0.753]) and triple negative
phenotype (p < .001; HR 1.068 [CI 0.933–1.125]) affected
BS statistically significantly (Table 2). KPS, ChT prior to
RT, local response, concomitant bisphosphonates, ortho-
pedic corset and pathological fractures prior to RT did not
statistically significantly influence BS (Table 2).
Discussion
Breast cancer patients suffering from bone metastases
of the spine represent a large patient group at most RT
facilities. An important indication for RT treatment in
these patients is instability, which is often associated
with increased pain, profoundly reduced activity in
daily life (ADL) and consequently severely impaired
QoL. Unstable SBM may therefore be associated with
shortened survival. We found OS and BS to be substan-
tially shorter in our analysis with only 50 and 12 %, re-
spectively, alive after 5 years compared to our previous
study on osteolytic SBM in women with breast cancer
[12]. Further studies have reported even worse survival
rates in women with bone metastases [15], but this may
be explained by a selection bias of only including pa-
tients with a follow-up of at least 6 months in our
study. In an earlier small prospective study we already
reported even lower survival rates in a population of
patients with unstable metastases from various solid tu-
mors [16]. In another study on patients with metastatic
lung cancer we did not find any difference in survival
between patients with stable and unstable SBM [17].
We believe that this was due to the extremely short
survival time of those patients with metastatic lung
cancer. Women with metastatic breast cancer have a
more favorable prognosis than those with other solidFig. 1 Overall survivaltumors, e.g. lung cancer, and instability, possibly due to
its associated morbidity, seems to be a relevant factor
for long-term survival.
We found an age of more than 50 years, the presence
of multiple SBM and triple negative phenotype to be
associated with a worse prognosis after first diagnosis
of bone metastases. In a recent study Bollen et al. [18]
reported a median survival time of 22.5 months (95 %
CI 18.0–26.9) for the receptor positive category and
6.7 months (95 % CI 2.4–10.9) for the triple negative
category (p < 0.001). Therefore, patients with bone me-
tastases from triple negative breast cancer have a sig-
nificantly worse prognosis than those with a receptor
positive phenotype.
According to the literature, another important prog-
nostic factor for survival is the existence of additional
extra-skeletal metastases [19]. In our analysis we were
only able to demonstrate the prognostic relevance of
age, the presence of a solitary metastasis and triple-
negative phenotype. We believe this to be due to thesurvival
HR 95 % CI p-value
Age 1.036 1.015–1.057 <0.001
KPS 1.000 0.981–1.019 0.997
Chemotherapy 1.452 0.926–2.277 0.104
Number of metastases 0.469 0.292–0.753 0.002
Local response 1.071 0.661–1.736 0.779
Bisphosphonates 1.109 0.477–2.577 0.810
Orthopedic corset 0.821 0.500–1.350 0.437
Pathological fracture 1.533 0.614–3.827 0.360
Luminal A 1.538 0.998–2.167 0.945
Luminal B 1.152 0.876–1.825 0.745
HER2 1.472 0.977–1.957 0.628
Triple negative 1.068 0.933–1.125 <0.001
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in our study cohort.
Conclusions
This analysis demonstrated a short survival of breast can-
cer patients with unstable SBM. Importantly, we presented
a correlation between age, presence of a solitary metasta-
sis, triple-negative phenotype, and survival. This may have
an impact on therapeutic decisions in the future. The re-
sults offer a rationale for future prospective investigations.
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